Why One Positive Lyme Test Is Not a Diagnosis: Two-Tier Serology Explained

A single positive result is a starting point, not a verdict

One positive Lyme antibody test does not establish that a person has Lyme disease. The CDC recommends a two-step (two-tier) serologic process, and a reactive first test means the sample advances to a second confirmatory test, not that the diagnosis is settled. These assays detect the body's antibody response to Borrelia burgdorferi rather than the bacterium itself, so they can be falsely negative in the first weeks of infection and can stay positive for years after a cure. When the same test is run on someone with little real chance of exposure, a large share of the positives that come back are false.

How the two-tier algorithm works

The CDC's diagnosis and testing guidance describes a two-step serologic process that uses FDA-cleared assays on the same blood sample. If the first step is negative, testing stops and the result is reported as negative. Only a positive or equivocal first step advances to the second step. The point of the structure is that a single reactive assay is not meant to stand alone.

Standard versus modified two-tier testing

In standard two-tier testing (STTT), the first step is an enzyme immunoassay (EIA) and the second is a Western blot, also called an immunoblot. The immunoblot reports separate IgM and IgG bands scored against defined criteria.

Since 2019, a modified two-tier testing (MTTT) option has been available. On July 29, 2019, the FDA cleared several assays that allow a second EIA to stand in for the Western blot, and the CDC endorsed the change in an August 2019 MMWR notice. Its language was specific: serologic assays that use an EIA rather than a western immunoblot in a two-test format are acceptable alternatives when the FDA has cleared them for that purpose. Two EIAs run in sequence are faster and easier to read than a blot, which is why many laboratories now use the approach. Either way the logic is identical. The second test exists to filter out the non-specific reactivity that a single EIA generates.

Why the test lags early infection

Antibodies take time to build. The CDC notes that serologic assays may be falsely negative during the first four to six weeks after infection, which is exactly the window when people are most likely to notice a tick bite or an early rash. Sensitivity in early localized disease is low, and the characteristic expanding rash called erythema migrans is often present before the antibody response becomes measurable. That is why erythema migrans in a person with plausible exposure is grounds for treatment on its own, and why a negative test that early does not rule the disease out. Sensitivity rises as the infection disseminates, and by the later stages the two-tier approach detects the large majority of true cases.

A related trap sits at the other end of the timeline. Early antibiotic treatment can blunt the antibody response, so the CDC cautions that patients treated promptly may be less likely to seroconvert at all.

The 30-day rule for IgM

IgM antibodies appear early and are prone to cross-reacting with unrelated exposures. The CDC's interpretation guidance is blunt about the consequence: a positive IgM result should be disregarded if the patient has been ill for more than 30 days. Someone with weeks or months of vague symptoms who tests IgM-positive and IgG-negative has, under the algorithm, a result that should not be read as evidence of Lyme disease. Leaning on a lone IgM band is one of the most common ways a non-diagnosis gets mistaken for a diagnosis.

Why a positive can persist after cure

Serology measures immune memory, and that memory does not switch off when an infection clears. The CDC's reporting and interpretation guidance is explicit that once antibody titers rise they can remain elevated for months to years and cannot be used to determine cure. A person who was infected and successfully treated can test positive long afterward. Repeating serology to check whether treatment worked, or reading a later positive as relapse, misreads what the assay can do. There is no test of cure in Lyme serology.

Why testing without exposure inflates false positives

This is where pretest probability matters. No antibody test is perfectly specific, so a small fraction of people who have never been infected will still test positive. When you test a group with a genuine chance of exposure, recent tick contact, a compatible illness, or time in an endemic area, most positives reflect real infection. When you test people with nonspecific fatigue and no plausible exposure, the pool of true cases is tiny, and the false positives can outnumber them. The two-tier structure raises specificity precisely to counter this, yet it cannot rescue a test ordered for the wrong person. Using Lyme serology as a broad screen for undifferentiated symptoms, without supporting history, tends to manufacture confusion rather than resolve it.

This article explains how a diagnostic algorithm works and is educational, not medical advice. Testing and treatment decisions belong with a qualified clinician who can weigh the full clinical picture.

The bottom line

A Lyme diagnosis rests on exposure, clinical findings, and correctly interpreted two-tier serology considered together. A single reactive band, an IgM read past its window, or a positive left over from an old and treated infection is a different thing altogether. The algorithm was built so that no single number ever has to carry the diagnosis by itself.